Article
Immunology
Constantina Boikos, Mahrukh Imran, Van Hung Nguyen, Thierry Ducruet, Gregg C. Sylvester, James A. Mansi
Summary: MF59(R)-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) demonstrate enhanced immune response in older adults compared to standard, quadrivalent inactivated influenza vaccines (IIV4). The study shows that aIIV3 is more effective than IIV4 in preventing influenza-related medical encounters in both the 2017-2018 and 2018-2019 seasons, with HD-IIV3 showing comparable effectiveness.
Article
Immunology
Hannah Chung, Michael A. Campitelli, Sarah A. Buchan, Aaron Campigotto, Branson Chen, Natasha S. Crowcroft, Vinita Dubey, Jonathan B. Gubbay, Timothy Karnauchow, Kevin Katz, Allison J. McGeer, J. Dayre McNally, Samira Mubareka, Michelle Murti, David C. Richardson, Laura C. Rosella, Kevin L. Schwartz, Marek Smieja, George Zahariadis, Jeffrey C. Kwong
Summary: The effectiveness of influenza vaccine against laboratory-confirmed influenza was similar between statin users and nonusers. However, statin users had a higher risk of influenza infection compared to nonusers, regardless of vaccination status. This study suggests that statin use may affect the effectiveness of influenza vaccine and increase the risk of influenza infection.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Geriatrics & Gerontology
Jessica Bartoszko, Mark Loeb
Summary: Influenza is an acute respiratory infection that can be prevented through vaccination. Despite older adults having the highest burden of influenza infection, vaccine effectiveness is lowest in this population due to immune senescence. Possible strategies to tackle this issue include adjuvant and high-dose vaccines, as well as increasing vaccine uptake to induce herd immunity.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)
Article
Immunology
Hannah Chung, Sarah A. Buchan, Aaron Campigotto, Michael A. Campitelli, Natasha S. Crowcroft, Vinita Dubey, Jonathan B. Gubbay, Timothy Karnauchow, Kevin Katz, Allison J. McGeer, J. Dayre McNally, Samira Mubareka, Michelle Murti, David C. Richardson, Laura C. Rosella, Kevin L. Schwartz, Marek Smieja, George Zahariadis, Jeffrey C. Kwong
Summary: This study estimated the effectiveness of influenza vaccine against mortality in older adults following laboratory-confirmed influenza in Ontario, Canada. The results showed that the vaccine had a significant impact on reducing all-cause mortality, especially during the 2014-2015 influenza season. Factors such as influenza subtype and COPD also played a role in mortality outcomes.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Katherine Williams, Mary G. Krauland, Lee H. Harrison, John Williams, Mark S. Roberts, Richard K. Zimmerman
Summary: The study suggests that a two-dose influenza vaccine regimen could effectively reduce flu cases and hospitalizations in older adults, especially during late-peak flu seasons.
Review
Geriatrics & Gerontology
Andreia N. Cadar, Dominique E. Martin, Jenna M. Bartley
Summary: The decline in immune response with age presents a challenge in combating diseases later in life, particularly influenza infection in older adults. Existing vaccines targeting older adults have not been effective enough in reducing the burden of flu. Recent geroscience research suggests that targeting biological aging may improve age-related declines, including vaccine responses. This review proposes alternative vaccine platforms and interventions targeting inflammation, cellular senescence, microbiome disturbances, and mitochondrial dysfunction to enhance vaccine responses and overall immune resilience in older adults.
Article
Infectious Diseases
Alexander Domnich, Donatella Panatto, Elena Pariani, Christian Napoli, Maria Chironna, Ilaria Manini, Caterina Rizzo, Andrea Orsi, Giancarlo Icardi
Summary: This study aimed to compare the relative vaccine effectiveness of MF59-adjuvanted trivalent vaccine and non-adjuvanted quadrivalent vaccine against severe laboratory-confirmed influenza. The results showed that the MF59-adjuvanted vaccine was more effective in preventing severe acute respiratory infection.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Kailey Hughes, Donald B. Middleton, Mary Patricia Nowalk, Goundappa K. Balasubramani, Emily T. Martin, Manjusha Gaglani, H. Keipp Talbot, Manish M. Patel, Jill M. Ferdinands, Richard K. Zimmerman, Fernanda P. Silveira
Summary: This study evaluated the vaccine effectiveness against influenza hospitalization among immunocompromised adults during the 2017-2018 influenza season. The results showed that while immunocompromised adults had a higher vaccination rate, their protection against influenza was lower, with a vaccine effectiveness of 33% in the overall adult population. Further research is needed to assess vaccine effectiveness among different immunocompromising conditions and explore ways to improve effectiveness for immunocompromised individuals.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Hana M. El Sahly, Robert L. Atmar, Eli Sendra, Ashley Wegel, Wendy A. Keitel
Summary: The study concluded that the combination of topical imiquimod with ID MIV A/H5N1 was safe but did not result in improved serologic responses to the vaccine.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Geriatrics & Gerontology
Kenneth E. Schmader, Christine K. Liu, Brendan Flannery, Wes Rountree, Heidi Auerbach, Elizabeth D. Barnett, Elizabeth P. Schlaudecker, Christopher A. Todd, Marek Poniewierski, Mary A. Staat, Theresa Harrington, Rongxia Li, Karen R. Broder, Emmanuel B. Walter
Summary: This study compared the antibody titers of different strains of influenza after the administration of adjuvanted inactivated influenza vaccine (aIIV) and high-dose inactivated influenza vaccine (HD-IIV) in older adults. The results showed no significant differences in immune responses between the two vaccines, but the seroconversion rate for the H3N2 strain was lower for aIIV compared to HD-IIV.
Article
Cell Biology
Chih-Hung Chou, Subhasis Mohanty, Heather A. Kang, Lingjia Kong, Julian Avila-Pacheco, Samit R. Joshi, Ikuyo Ueda, Lesley Devine, Khadir Raddassi, Kerry Pierce, Sarah Jeanfavre, Kevin Bullock, Hailong Meng, Clary Clish, Fabio R. Santori, Albert C. Shaw, Ramnik J. Xavier
Summary: A study on the metabolic changes and molecular markers associated with influenza vaccine response in different age groups provides insights for the development of effective vaccines. The research found age-related differences in metabolic baselines and identified specific metabolites and genes indicative of immune response to vaccination.
Review
Economics
Desmond Loong, Ba' Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Mueller, Sharon E. Straus, Andrea C. Tricco, Wanrudee Isaranuwatchai
Summary: Older adults are at high risk of influenza-related complications or hospitalization. This systematic review evaluates the cost-effectiveness of different influenza vaccine options for older adults. The findings suggest that quadrivalent inactivated vaccine (QIV), high-dose trivalent inactivated vaccine (TIV-HD), and adjuvanted trivalent inactivated vaccine (TIV-ADJ) are cost-effective compared to trivalent inactivated vaccine (TIV), with a willingness to pay threshold of $50,000 per quality-adjusted life-year. Future studies should employ robust methodologies, such as real-world evaluations or modeling studies, to account for methodological, structural, and parameter uncertainty.
Article
Public, Environmental & Occupational Health
Alexander Domnich, Andrea Orsi, Matilde Ogliastro, Carlo-Simone Trombetta, Marianna Scarpaleggia, Chiara Ceccaroli, Carla Amadio, Anna Raffo, Luca Berisso, Alla Yakubovich, Giacomo Zappa, Daniela Amicizia, Donatella Panatto, Giancarlo Icardi
Summary: Missed opportunities for seasonal influenza vaccination are common among older adults, and the co-administration of vaccines is relatively low. Increasing vaccine co-administration rates and implementing tailored health promotion interventions can help address these missed opportunities.
EUROPEAN JOURNAL OF PUBLIC HEALTH
(2023)
Article
Immunology
Joshua D. Doyle, Lauren Beacham, Emily T. Martin, H. Keipp Talbot, Arnold Monto, Manjusha Gaglani, Donald B. Middleton, Fernanda P. Silveira, Richard K. Zimmerman, Elif Alyanak, Emily R. Smith, Brendan L. Flannery, Melissa Rolfes, Jill M. Ferdinands
Summary: The study found that during two US influenza seasons, the effectiveness of high-dose influenza vaccine for preventing influenza hospitalizations in adults aged >= 65 years was low to moderate, with high-dose vaccine offering greater effectiveness compared to standard-dose vaccine. None of these findings were statistically significant.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Min Joo Choi, Gyeongseon Shin, Daewon Kang, Jae-Ok Lim, Yun-Kyung Kim, Won Suk Choi, Jae-Won Yun, Ji Yun Noh, Joon Young Song, Woo Joo Kim, Sang-Eun Choi, Hee Jin Cheong
Summary: This study evaluated the cost-effectiveness of different influenza vaccines under the Korean National Immunization Program for different age groups. The results showed that the high-dose quadrivalent vaccine (HD-QIV) was the most cost-effective choice for adults aged 65 years or older. For other high-risk age groups, the introduction of influenza vaccine programs, whether using the traditional trivalent vaccine (TIV) or quadrivalent vaccine (QIV), was cost-effective.
Article
Surgery
Kristina J. Nicholson, Kenneth J. Smith, Kelly L. McCoy, Sally E. Carty, Linwah Yip
Article
Public, Environmental & Occupational Health
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2020)
Article
Geriatrics & Gerontology
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2020)
Article
Pediatrics
Nader Shaikh, Vinod Rajakumar, Caitlin G. Peterson, Jillian Gorski, Anastasia Ivanova, Lisa Gravens Muller, Yosuke Miyashita, Kenneth J. Smith, Tej Mattoo, Hans G. Pohl, Ranjiv Mathews, Saul P. Greenfield, Steven G. Docimo, Alejandro Hoberman
FRONTIERS IN PEDIATRICS
(2020)
Article
Surgery
Chethan M. Puttarajappa, Rajil B. Mehta, Mark S. Roberts, Kenneth J. Smith, Sundaram Hariharan
Summary: The study found that screening for subclinical rejection more than once during the first year after kidney transplantation is not economically reasonable, with a one-time screening at peak incidence being the preferred option. Screening with protocol biopsy was favored over using biomarkers.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Immunology
Angela R. Wateska, Mary Patricia Nowalk, Hawre Jalal, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Summary: The study indicates that further research on parameters of pneumococcal vaccine uptake programs is not supported at commonly cited US cost-effectiveness benchmarks in adults. It is justifiable to conduct further research to reduce uncertainty in other aspects of adult pneumococcal vaccination.
Article
Immunology
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman
Summary: The COVID-19 pandemic has led to declines in childhood PCV13 vaccination rates, which could result in increased pneumococcal disease rates in seniors, impacting the economic favorability of PCV13 vaccination in older adults. Absolute decreases of over 50% in pediatric PCV13 vaccination over a two-year period would be needed to make intensified PCV13 use economically favorable in non-immunocompromised seniors.
Article
Clinical Neurology
Clark A. Veet, Stephen Capone, David Panczykowski, Natasha Parekh, Kenneth J. Smith, Dong H. Kim, H. Alex Choi, Spiros L. Blackburn
Summary: The study found that immediate surgical treatment is the most cost-effective strategy for small unruptured anterior circulation aneurysms, particularly in patients under 70 years of age. The cost-effectiveness of immediate surgery is highly sensitive to factors such as diagnosis age, rupture rate, and surgical complication risk.
CEREBROVASCULAR DISEASES
(2022)
Article
Health Care Sciences & Services
Margaret F. Zupa, Ronald A. Codario, Kenneth J. Smith
Summary: The study found that for patients with Type 2 diabetes and cardiovascular disease, semaglutide is likely to be more cost-effective than empagliflozin added to usual treatment.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Oncology
Lauren E. Sigler, Andrew D. Althouse, Teresa H. Thomas, Robert M. Arnold, Douglas White, Thomas J. Smith, Edward Chu, Margaret Rosenzweig, Kenneth J. Smith, Yael Schenker
Summary: This study assessed the effect of an oncology nurse-led primary palliative care intervention on illness expectations among patients with advanced cancer. The results showed little difference in realistic illness expectations at 3 months between the intervention and standard care groups. The study suggests that illness expectations are difficult to change among patients with advanced cancer.
JCO ONCOLOGY PRACTICE
(2022)
Article
Nutrition & Dietetics
Vikram K. Raghu, Wednesday M. A. Sevilla, Dale E. King, Feras Alissa, Scott Rothenberger, Kenneth J. Smith, Simon P. Horslen, Jeffrey A. Rudolph
Summary: Centers for intestinal rehabilitation and transplantation commonly use alternative intravenous lipid emulsions (ILEs), which is significant for decision support in specific clinical scenarios.
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
(2022)
Article
Infectious Diseases
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman
Summary: The general population recommendations for PCV20 use are more economically reasonable for both Black and non-Black older adult populations compared to PCV15/PPSV23. If a single vaccine can increase the uptake, especially in underserved populations, the use of PCV20 becomes even more favorable.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Immunology
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Summary: The introduction summarizes the CDC's recommendations for pneumococcal vaccination in older adults and the potential benefits of an in-development 21-valent vaccine (PCV21) compared to current recommendations. A decision model was used to compare the cost-effectiveness of PCV21 to current vaccines in Black and non-Black cohorts. The results indicate that PCV21 is likely to be economically and clinically favorable in older adults.
Article
Economics
Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Summary: This study estimated the societal cost of racial disparities in pneumococcal disease among US adults aged >= 50 years. The findings suggest that the racial disparities in costs are substantial and implementing policies and interventions could reduce these costs and improve health.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
(2023)
Article
Health Policy & Services
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
JOURNAL OF COMMUNITY HEALTH
(2020)
